Working… Menu

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03655613
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : June 6, 2019
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Apollomics (Australia) Pty. Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : December 15, 2020